Home » Topics » BioWorld Science

BioWorld Science
RSS

DNA-PK activates survival kinase AKT in response to DNA damage

Jan. 20, 2022

Red Bull GmbH presents dopamine reuptake inhibitors

Jan. 20, 2022

Medshine Discovery synthesizes new JAK3 inhibitors

Jan. 20, 2022

Sun Pharmaceutical Industries divulges GIPR and GLP-1 receptor dual agonists

Jan. 20, 2022

Jiangsu Hengrui Medicine and Shanghai Hengrui Pharmaceutical patent new ATR kinase inhibitors

Jan. 20, 2022

Kallyope presents new AMPK activators

Jan. 20, 2022

Nanodecoys scavenge RANKL and TNF-alpha for osteoporosis treatment

Jan. 20, 2022

Targeting DICAM impedes migration of disease-inducing leukocytes into the CNS in multiple sclerosis

Jan. 20, 2022

Oncostatin M blockade ameliorates severe asthma

Jan. 20, 2022

Amyloid aggregates differ in familial and sporadic AD

Jan. 19, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Will Ovid’s golden age of KCC2 metamorph CNS?
BioWorld
The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...
BMS-Hengrui deal strikes panic in Washington
BioWorld
On the heels of the multibillion-dollar licensing deal between Bristol Myers Squibb Co. and Jiangsu Hengrui Pharmaceuticals Co. Ltd., Chairman John Moolenaar...